Zoledronic acid epigenetically alleviates high-glucose-suppressed osteogenic differentiation of MC3T3-E1 cells
OBJECTIVE: Due to the impact of excessive glucose on osteogenic differentiation, diabetic osteopathy frequently results in skeletal fragility, osteoporosis, and bone pain. Zoledronic acid, a bisphosphonate (BP) that effectively inhibits osteoclastic bone resorption is given yearly to improve bone mineral density (BMD) in patients with osteoporosis. However, the detailed molecular mechanisms remained unclear. This study investigates the possible pathways by which zoledronic acid regulates osteogenesis when blood glucose levels are high.
MATERIALS AND METHODS: MC3T3-E1 cells were treated with one mM zoledronic acid or not in a standard or high glucose culture medium. A quantitative polymerase chain reaction (qPCR) assay was utilized to assess the expression of the target candidate genes, including RUNX2, MALAT1, miR-133, miR-20a, and miR-204.
RESULTS: In a high-glucose condition, zoledronic acid treatment significantly lowered MALAT1 (p < 0.0001) and miR-20a (p < 0.0001) expression. Conversely, in a high-glucose condition, RUNX2, miR-133, and miR-204 expressions were found to be significantly increased in the zoledronic acid treatment group as compared to no treatment (all p < 0.0001).
CONCLUSIONS: In conclusion, under a high-glucose environment, zoledronic acid can modulate the expression of the RUNX2 transcription factor through epigenetic regulation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
European review for medical and pharmacological sciences - 27(2023), 16 vom: 05. Aug., Seite 7576-7581 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, H-L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6XC1PAD3KF |
|---|
| Anmerkungen: |
Date Completed 06.09.2023 Date Revised 19.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.26355/eurrev_202308_33409 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361656394 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361656394 | ||
| 003 | DE-627 | ||
| 005 | 20231226085613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.26355/eurrev_202308_33409 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM361656394 | ||
| 035 | |a (NLM)37667934 | ||
| 035 | |a (PII)33409 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, H-L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Zoledronic acid epigenetically alleviates high-glucose-suppressed osteogenic differentiation of MC3T3-E1 cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.09.2023 | ||
| 500 | |a Date Revised 19.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: Due to the impact of excessive glucose on osteogenic differentiation, diabetic osteopathy frequently results in skeletal fragility, osteoporosis, and bone pain. Zoledronic acid, a bisphosphonate (BP) that effectively inhibits osteoclastic bone resorption is given yearly to improve bone mineral density (BMD) in patients with osteoporosis. However, the detailed molecular mechanisms remained unclear. This study investigates the possible pathways by which zoledronic acid regulates osteogenesis when blood glucose levels are high | ||
| 520 | |a MATERIALS AND METHODS: MC3T3-E1 cells were treated with one mM zoledronic acid or not in a standard or high glucose culture medium. A quantitative polymerase chain reaction (qPCR) assay was utilized to assess the expression of the target candidate genes, including RUNX2, MALAT1, miR-133, miR-20a, and miR-204 | ||
| 520 | |a RESULTS: In a high-glucose condition, zoledronic acid treatment significantly lowered MALAT1 (p < 0.0001) and miR-20a (p < 0.0001) expression. Conversely, in a high-glucose condition, RUNX2, miR-133, and miR-204 expressions were found to be significantly increased in the zoledronic acid treatment group as compared to no treatment (all p < 0.0001) | ||
| 520 | |a CONCLUSIONS: In conclusion, under a high-glucose environment, zoledronic acid can modulate the expression of the RUNX2 transcription factor through epigenetic regulation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Zoledronic Acid |2 NLM | |
| 650 | 7 | |a 6XC1PAD3KF |2 NLM | |
| 650 | 7 | |a Core Binding Factor Alpha 1 Subunit |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a MIRN204 microRNA, human |2 NLM | |
| 700 | 1 | |a Hu, J-P |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J-F |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Q |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European review for medical and pharmacological sciences |d 1997 |g 27(2023), 16 vom: 05. Aug., Seite 7576-7581 |w (DE-627)NLM09387944X |x 2284-0729 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:16 |g day:05 |g month:08 |g pages:7576-7581 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26355/eurrev_202308_33409 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 16 |b 05 |c 08 |h 7576-7581 | ||